From Wikipedia, the free encyclopedia

The European Registry of Hereditary Pancreatitis and Pancreatic Cancer (EUROPAC) was started by John Neoptolemos and colleagues [1] in 1997 and has become the world’s most extensive study on hereditary pancreatic diseases. It enabled discovery of several genetic characteristics causative for hereditary pancreatitis and familial pancreatic cancer. [2] [3] [4] [5]

Description

EUROPAC is based at the Royal Liverpool University Hospital and it is supported by grants from Cancer Research UK, the European Union, the National Institute for Health and Care Research (NIHR), Pancreatic Cancer UK, NHS England, and Cheshire and Merseyside Cancer Alliance.

It maintains a registry of families in whom there is thought to be an increased risk of pancreatic cancer. Studies have shown that an increased risk of cancer is inferred if two or more first-degree relatives have the condition. In addition to the Familial Pancreatic Cancer (FPC) registry, EUROPAC offers screening for early pancreatic cancer on a research basis in those deemed at high risk for the development of the condition. Screening for early pancreatic cancer involves several different blood tests and scans and is usually undertaken from the age of 40 in high-risk individuals.

Patients who have a family history of pancreatic cancer or pancreatitis may be eligible to join the study. Referrals are made via genetic counsellors, GPs, other consultants or directly via email.

The research team based in Liverpool includes Annabelle Boughey (EUROPAC Operations Manager), Paul Thomas (EUROPAC Coordinator) Phil Hopley (clinical research fellow), Professor Christopher Halloran ( principal investigator) and Professor William Greenhalf (lead scientist).

References

  1. ^ Finch, Margaret D.; Howes, Nathan; Ellis, Ian; Mountford, Roger; Sutton, Robert; Raraty, Michael; Neoptolemos, John P. (1997). "Hereditary Pancreatitis and Familial Pancreatic Cancer". Digestion. 58 (6): 564–569. doi: 10.1159/000201502. ISSN  0012-2823. PMID  9438603.
  2. ^ Threadgold, J (2002-05-01). "The N34S mutation of SPINK1 (PSTI) is associated with a familial pattern of idiopathic chronic pancreatitis but does not cause the disease". Gut. 50 (5): 675–681. doi: 10.1136/gut.50.5.675. ISSN  0017-5749. PMC  1773194. PMID  11950815.
  3. ^ Howes, Nathan; Lerch, Markus M.; Greenhalf, William; Stocken, Deborah D.; Ellis, Ian; Simon, Peter; Truninger, Kaspar; Ammann, Rudi; Cavallini, Giorgio; Charnley, Richard M.; Uomo, Generoso (March 2004). "Clinical and genetic characteristics of hereditary pancreatitis in Europe". Clinical Gastroenterology and Hepatology. 2 (3): 252–261. doi: 10.1016/S1542-3565(04)00013-8. PMID  15017610.
  4. ^ McFaul, C D (2006-02-01). "Anticipation in familial pancreatic cancer". Gut. 55 (2): 252–258. doi: 10.1136/gut.2005.065045. ISSN  0017-5749. PMC  1856528. PMID  15972300.
  5. ^ Grocock, C. J.; Rebours, V.; Delhaye, M. N.; Andren-Sandberg, A.; Weiss, F. U.; Mountford, R.; Harcus, M. J.; Niemczyck, E.; Vitone, L. J.; Dodd, S.; Jorgensen, M. T. (2010-03-01). "The variable phenotype of the p.A16V mutation of cationic trypsinogen (PRSS1) in pancreatitis families". Gut. 59 (3): 357–363. doi: 10.1136/gut.2009.186817. ISSN  0017-5749. PMID  19951905. S2CID  983450.
From Wikipedia, the free encyclopedia

The European Registry of Hereditary Pancreatitis and Pancreatic Cancer (EUROPAC) was started by John Neoptolemos and colleagues [1] in 1997 and has become the world’s most extensive study on hereditary pancreatic diseases. It enabled discovery of several genetic characteristics causative for hereditary pancreatitis and familial pancreatic cancer. [2] [3] [4] [5]

Description

EUROPAC is based at the Royal Liverpool University Hospital and it is supported by grants from Cancer Research UK, the European Union, the National Institute for Health and Care Research (NIHR), Pancreatic Cancer UK, NHS England, and Cheshire and Merseyside Cancer Alliance.

It maintains a registry of families in whom there is thought to be an increased risk of pancreatic cancer. Studies have shown that an increased risk of cancer is inferred if two or more first-degree relatives have the condition. In addition to the Familial Pancreatic Cancer (FPC) registry, EUROPAC offers screening for early pancreatic cancer on a research basis in those deemed at high risk for the development of the condition. Screening for early pancreatic cancer involves several different blood tests and scans and is usually undertaken from the age of 40 in high-risk individuals.

Patients who have a family history of pancreatic cancer or pancreatitis may be eligible to join the study. Referrals are made via genetic counsellors, GPs, other consultants or directly via email.

The research team based in Liverpool includes Annabelle Boughey (EUROPAC Operations Manager), Paul Thomas (EUROPAC Coordinator) Phil Hopley (clinical research fellow), Professor Christopher Halloran ( principal investigator) and Professor William Greenhalf (lead scientist).

References

  1. ^ Finch, Margaret D.; Howes, Nathan; Ellis, Ian; Mountford, Roger; Sutton, Robert; Raraty, Michael; Neoptolemos, John P. (1997). "Hereditary Pancreatitis and Familial Pancreatic Cancer". Digestion. 58 (6): 564–569. doi: 10.1159/000201502. ISSN  0012-2823. PMID  9438603.
  2. ^ Threadgold, J (2002-05-01). "The N34S mutation of SPINK1 (PSTI) is associated with a familial pattern of idiopathic chronic pancreatitis but does not cause the disease". Gut. 50 (5): 675–681. doi: 10.1136/gut.50.5.675. ISSN  0017-5749. PMC  1773194. PMID  11950815.
  3. ^ Howes, Nathan; Lerch, Markus M.; Greenhalf, William; Stocken, Deborah D.; Ellis, Ian; Simon, Peter; Truninger, Kaspar; Ammann, Rudi; Cavallini, Giorgio; Charnley, Richard M.; Uomo, Generoso (March 2004). "Clinical and genetic characteristics of hereditary pancreatitis in Europe". Clinical Gastroenterology and Hepatology. 2 (3): 252–261. doi: 10.1016/S1542-3565(04)00013-8. PMID  15017610.
  4. ^ McFaul, C D (2006-02-01). "Anticipation in familial pancreatic cancer". Gut. 55 (2): 252–258. doi: 10.1136/gut.2005.065045. ISSN  0017-5749. PMC  1856528. PMID  15972300.
  5. ^ Grocock, C. J.; Rebours, V.; Delhaye, M. N.; Andren-Sandberg, A.; Weiss, F. U.; Mountford, R.; Harcus, M. J.; Niemczyck, E.; Vitone, L. J.; Dodd, S.; Jorgensen, M. T. (2010-03-01). "The variable phenotype of the p.A16V mutation of cationic trypsinogen (PRSS1) in pancreatitis families". Gut. 59 (3): 357–363. doi: 10.1136/gut.2009.186817. ISSN  0017-5749. PMID  19951905. S2CID  983450.

Videos

Youtube | Vimeo | Bing

Websites

Google | Yahoo | Bing

Encyclopedia

Google | Yahoo | Bing

Facebook